Matchpoint Therapeutics
Updated: October 09, 2026
CEO - Andre Turenne
Country: USA | Funding: $150M (+)
Founded: 2021
Website: https://matchpointtx.com/
Matchpoint Therapeutics integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses. Its lead asset MPT-062 is an oral T cell modulator that allows to treat autoimmune and inflammatory diseases.
Founded: 2021
Website: https://matchpointtx.com/
Matchpoint Therapeutics integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses. Its lead asset MPT-062 is an oral T cell modulator that allows to treat autoimmune and inflammatory diseases.
